Metabolic dysfunction-associated fatty liver disease - How relevant is this to primary care physicians and diabetologists?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 35086794.
- Also identified by DOI 10.1016/j.pcd.2022.01.005.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Metabolic-dysfunction associated fatty liver disease (MAFLD) is a newly introduced entity hoping to more precisely define fatty liver disease. Despite the controversies surrounding MAFLD, the definition is getting more widely accepted by the global liver-health community. MAFLD represents a cohort of patients enriched with more advanced liver disease, cardio-renal and metabolic complications with increased mortality. This review aims to provide all primary care physicians and diabetologists with a clinical management update from a non-hepatologist's perspective, and a summary of important findings from recent studies to raise disease awareness and highlight the relevance of MAFLD to their daily clinical practice.
Medical subject headings
- Non-alcoholic Fatty Liver Disease
- Physicians, Primary Care